nad has been researched along with monocrotaline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernocchi, P; Ceconi, C; Curello, S; Ferrari, R; Pasini, E; Pedersini, P | 1 |
| Hanif, K; Kaur, G; Lingeshwar, P; Siddiqui, HH; Singh, N | 1 |
2 other study(ies) available for nad and monocrotaline
| Article | Year |
|---|---|
Skeletal muscle metabolism in experimental heart failure.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Cardiomegaly; Disease Models, Animal; Female; Heart Failure; Monocrotaline; Muscle, Skeletal; NAD; Organ Size; Oxidation-Reduction; Phosphocreatine; Rats; Rats, Sprague-Dawley | 1996 |
Poly (ADP-ribose) polymerase-1: an emerging target in right ventricle dysfunction associated with pulmonary hypertension.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; In Situ Nick-End Labeling; Isoquinolines; Male; Mitochondria; Mitochondrial Membranes; Monocrotaline; NAD; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-2; Ventricular Dysfunction, Right | 2015 |